ALLO - Allogene Therapeutics GAAP EPS of -$0.54 beats by $0.06 revenue of $51M

Allogene Therapeutics press release (NASDAQ:ALLO): Q4 GAAP EPS of -$0.54 beats by $0.06. Revenue of $51K. The Company had $810 million in cash, cash equivalents, and investments as of December 31, 2021. Allogene expects full year GAAP Operating Expenses to be between $360 million and $390 million including estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities.

For further details see:

Allogene Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $51M